Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents

Advances in Enzyme Regulation

Volumn 38, Issue 1, 1998, Pages 3-18

  Cory, Ann H ^a   He, Ai Wu Ruth ^a   Cory, Joseph G ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3-DIHYDRO-1H-IMIDAZO(1,2-B)PYRAZOLE; 4-METHYL-5-AMINO-1-FORMYLISOQUINOLINE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; DEOXYADENOSINE DERIVATIVE; ENZYME INHIBITOR; HYDROXYUREA; ISOQUINOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE;

ANIMAL; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CULTURE; CELL DIVISION; COLON CANCER; CONFERENCE PAPER; DNA SYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; METABOLISM; MOUSE; NONHUMAN; TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DEOXYADENOSINES; DRUG RESISTANCE; ENZYME INHIBITORS; HUMANS; HYDROXYUREA; ISOQUINOLINES; LEUKEMIA; MICE; PYRAZOLES; RIBONUCLEOTIDE REDUCTASES; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0031856045     PISSN: 00652571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0065-2571(97)00003-4     Document Type: Conference Paper

References (42)

1. J. G. CORY, Role of ribonucleotide reductase in cell division, pp. 1-16 in Inhibitors of Nucleoside Diphosphate Reductase Activity, (J. G. CORY and A. H. CORY, eds.). Pergamon Press, New York (1989).
2. E. C. MOORE, Components and control of ribonucleotide reductase system of the rat, Advan. Enzyme Regul. 15, 101-114 (1977).
3. S. HOOPER, Ribonucleotide reductase of rabbit bone marrow - 1. Purification, properties and separation into two fractions, J. Biol. Chem. 247, 3336-3340 (1972).
4. J. G. CORY, A. E. FLEISCHER and J. B. MUNRO III, Reconstitution of ribonucleotide reductase from Ehrlich tumor cells, J. Biol. Chem. 253, 2898-2901 (1978).
5. L. THELANDER, S. ERIKSSON and M. AKERMAN, Ribonucleotide reductase from calf thymus. Separation of the enzyme into two nonidentical subunits, proteins M1 and M2, J. Biol. Chem. 255, 7426-7432 (1980).
6. C-H. CHANG and Y-C. CHENG, Demonstration of two components and association of adenosine diphosphate cytidine diphosphate reductase from cultured human lymphoblast cells (Molt-4F), Cancer Res. 39, 436-442 (1979).
7. L. THELANDER and P. BERG, Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase, Mol. Cell Biol. 6, 3433-3442 (1986).
8. I. W. CARAS and D. W. MARTIN JR, Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells, Mol. Cell Biol. 8, 2698-2704 (1988).
9. L. AAKERBLOM, A. EHRENBERG, A. GRASLUND, H. LANKINEN, P. REICHARD and L. THELANDER, Overproduction of the free-radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells, Proc. Natl. Acad. Sci. U.S.A. 78, 2159-2163 (1981).
10. S. ERIKSSON, L. THELANDER and M. AKERMAN, Allosteric regulation of calf thymus ribonucleotide diphosphate reductase, Biochemistry 18, 2948-2952 (1979).
11. J. G. CORY and A. E. FLEISCHER, Noncoordinate changes in the components of ribonucleotide reductase in mammalian cells, J. Biol. Chem. 257, 1263-1266 (1982).
12. E. H. RUBIN and J. G. CORY, Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells, Cancer Res. 46, 6165-6169 (1986).
13. J. G. CORY and A. E. FLEISCHER, Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy, Cancer Res. 39, 4600-4640 (1979).
14. J. G. CORY, A. SATO and L. LASATER, Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy, Advan. Enzyme Regul. 19, 139-150 (1981).
15. A. SATO, G. L. CARTER, P. E. BACON and J. G. CORY, Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture, Cancer Res. 42, 4353-4357 (1982).
16. M. MATSUMOTO, T. TIHAN and J. G. CORY, Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture, Cancer Chemother. Pharmacol. 26, 323-329 (1990).
17. M. MATSUMOTO, G. WECKBECKER and J. G. CORY, Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl) adenine in mice with L1210 leukemia cells, Cancer Commun. 2, 1-6 (1990).
18. G. L. CARTER and J. G. CORY, Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells, Cancer Res. 48, 5796-5799 (1988).
19. A. H. CORY, A. SATO, D. P. THOMPSON and J. G. CORY, Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, Oncology Res. 8, 449-456 (1996).
20. G. L. CARTER and J. G. CORY, Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase, Advan. Enzyme Regul. 29, 123-139 (1989).
21. J. G. CORY and G. L. CARTER, Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors, Cancer Res. 48, 839-843 (1988).
22. L. THELANDER and A. GRASLUND, Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone, J. Biol. Chem. 258, 4063-4066 (1983).
23. D. A. H. RITTBERG and J. A. WRIGHT, Relationships between sensitivity to hydroxyurea and 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazones (MAIQ) and ribonucleotide reductase RNR2 messenger RNA levels in strains of Saccharomyces cerevisiae, Biochem. Cell Biol. 67, 352-357 (1989).
24. J. G. CORY, L. LASATER and A. SATO, Effect of iron-chelating agents on inhibitors of ribonucleotide reductase, Biochem. Pharmacol. 30, 979-984 (1981).
25. G. L. CARTER, D. P. THOMPSON and J. G. CORY, Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase, Cancer Commun. I, 13-20 (1989).
26. C. E. JOHNSON, K. HUGHES and J. G. CORY, Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants, Cancer Commun. 3, 341-349 (1991).
27. G. RAPPA, A. LORICO, G. D. KRUB, A. H. CORY, J. G. CORY and A. SARTORELLI, Overexpression of the multi-drug resistance genes mdr1, mdr3 and mrp in L1210 cells resistant to inhibitors of ribonucleotide reductase, Biochem. Pharmacol. 54, 649-655 (1997).
28. J. G. CORY, D. L. DOWNES, A. H. CORY, K-J. SCHAPER and J. SEYDEL, Substituted 2-acylpyridine-a-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth, Anticancer Res. 14, 875-880 (1994).
29. J. G. CORY, G. L. CARTER, P. E. BACON, A. T'ANG and E. J. LIEN, Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N′-aminoguanidine derivations, Biochem. Pharmacol. 34, 2645-2650 (1985).
30. I. KJOLLER-LARSEN, B-M. SJOBERG and L. THELANDER, Characterization of the active site of ribonucleotide reductase of E. coli, bacteriophage T4 and mammalian cells by inhibition studies with hydroxyurea analogs, Eur. J. Biochem. 125, 75-81 (1982).
31. J. G. CORY, A. H. CORY, A. LORICO, G. RAPPA and A. SARTORELLI, Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, Anticancer Res. 17, 3185-3194 (1997).
32. D. P. THOMPSON, G. L. CARTER and J. G. CORY, Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells, Cancer Commun. 1, 253-260 (1989).
33. J. G. CORY, A. H. CORY, S. D. LONG, G. L. CARTER and C. E. JOHNSON, Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine, Cancer Res. 52, 2000-2003 (1992).
34. J. G. CORY, A. W. HE and A. H. CORY, Deoxyadenosine-resistant mouse leukemia L1210 cell lines with alterations in early response genes and p53, Anticancer Res. 16, 3483-3490 (1996).
35. K. KELLY, B. H. COCHRAN, C. D. STILES and P. LEDER, Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factors, Cell 35, 603-610 (1983).
36. R. MULLER, R. BRAVO, J. BURKHARDT and T. CURRAN, Induction of c-fos gene and protein by growth factors precedes activation of c-myc, Nature (Lond.) 312, 716-720 (1984).
37. M. DEAN, R. A. LEVINE, W. RAN, M. S. KINDY, G. E. SORENSHEIN and J. CAMPISI, Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact, J. Biol. Chem. 261, 9161-9166 (1986).
38. Y. YIN, M. A. TAINSKY, F. Z. BISCHOFF, L. C. STRONG and G. M. WAHL, Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant alleles, Cell 10, 937-948 (1992).
39. L. R. LIVINGSTONE, A. WHITE, J. SPROUSE, E. LIVANOS, T. JACKS and T. D. TLSTY, Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53, Cell 70, 923-935 (1992).
40. S. W. LOWE, H. E. RULEY, T. JACKS and D. E. HOUSMAN, p-53 dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell 74, 957-967 (1993).
41. A. W. HE and J. G. CORY, p53-independent WAF1 and GADD45 induction after DNA damage, Mol. Biol. Cell (Supplement) 7, 22a (1996).
42. A. W. HE and J. G. CORY, p53-independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines, Proc. Am. Assoc. Cancer Res. 38, 281 (1997).